151 related articles for article (PubMed ID: 15552635)
1. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
Dutta S; Reed RC; Cavanaugh JH
Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
[TBL] [Abstract][Full Text] [Related]
2. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
Reed RC; Dutta S
Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
[TBL] [Abstract][Full Text] [Related]
3. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
Dutta S; Reed RC
Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
[TBL] [Abstract][Full Text] [Related]
4. Divalproex-ER pharmacokinetics in older children and adolescents.
Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
[TBL] [Abstract][Full Text] [Related]
5. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
Garikipati V; Toops DS; Fang Q
Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
[TBL] [Abstract][Full Text] [Related]
7. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
[TBL] [Abstract][Full Text] [Related]
8. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
Reed RC; Dutta S
Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
[TBL] [Abstract][Full Text] [Related]
9. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
10. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
11. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
Dutta S; Reed RC
J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
Horne RL; Cunanan C
J Clin Psychopharmacol; 2003 Apr; 23(2):176-81. PubMed ID: 12640219
[TBL] [Abstract][Full Text] [Related]
13. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
Dutta S; Reed RC; O'Dea RF
Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
Gordi T; Hou E; Kasichayanula S; Berner B
Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
[TBL] [Abstract][Full Text] [Related]
15. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
Roberts D; Easter D; O'Bryan-Tear G
Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.
Freitag FG; Collins SD; Carlson HA; Goldstein J; Saper J; Silberstein S; Mathew N; Winner PK; Deaton R; Sommerville K;
Neurology; 2002 Jun; 58(11):1652-9. PubMed ID: 12058094
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
Dutta S; Zhang Y
Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Zhang Y; Lee LL; O'Dea R
Biopharm Drug Dispos; 2004 Nov; 25(8):353-7. PubMed ID: 15378556
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
20. Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers.
Zakeri-Milani P; Nemati M; Ghanbarzadeh S; Hamishehkar H; Valizadeh H
Arzneimittelforschung; 2011; 61(8):439-43. PubMed ID: 21950147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
